We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Uniqure Nv
8 own
13 watching
Current Price
$0
$-0.05
(-0.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
941.71M
52-Week High
28.255
52-Week Low
12.98
Average Volume
0.05M
Dividend Yield
--
P/E Ratio
5.0703
Market Capitalization941.71M52-Week High28.25552-Week Low12.98Average Volume0.05MDividend Yield--P/E Ratio5.0703What does the Uniqure Nv do?
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More
How much money does Uniqure Nv make?
News & Events about Uniqure Nv.
Globe Newswire
3 months ago
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and ...
Globe Newswire
3 months ago
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntingtons disease clinical update from U.S. Phase I/II trial expected in second quarter 2023 ~ ~Hosted virtual investor ...
Globe Newswire
3 months ago
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and generate elevated and sustained factor IX levels for years after a one-time infusion...
Globe Newswire
5 months ago
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients ...
PR Newswire
5 months ago
CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable...
Frequently Asked Questions
Frequently Asked Questions
What is Uniqure Nv share price today?
Can Indians buy Uniqure Nv shares?
How can I buy Uniqure Nv shares from India?
Can Fractional shares of Uniqure Nv be purchased?
What are the documents required to start investing in Uniqure Nv stocks?
What is today’s traded volume of Uniqure Nv?
What is today’s market capitalisation of Uniqure Nv?
What is the 52-Week High and Low Range of Uniqure Nv?
What percentage is Uniqure Nv down from its 52-Week High?
What percentage is Uniqure Nv up from its 52-Week Low?
Current Price
$0
$-0.05
(-0.25%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.